Peer-Reviewed Publication
Am J Hypertens2022;35(12):1006-1013.December 8, 2022Journal Article
Clinical Risk Factors For Kidney Tubule Biomarker Abnormalities Among Hypertensive Adults With Reduced eGFR in the SPRINT Trial.
Jesse C Ikeme1, Ronit Katz2, Anthony N Muiru1, Michelle M Estrella1, Rebecca Scherzer1, Pranav S Garimella3, Stein I Hallan4,5, Carmen A Peralta1,6, Joachim H Ix3,7,8, Michael G Shlipak1
1Kidney Health Research Collaborative, University of California, San Francisco and San Francisco Veterans Affairs Health Care System, San Francisco, California, USA.
2Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA.
3Division of Nephrology and Hypertension, Department of Medicine, University of California San Diego, San Diego, California, USA.
4Department of Nephrology, St Olav's Hospital, Trondheim, Norway.
5Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim,Norway.
6Cricket Health, Inc., San Francisco, California, USA.
7Herbert Wertheim School of Public Health, University of California San Diego, San Diego, California, USA.
8Nephrology Section, Veterans Affairs San Diego Healthcare System, La Jolla, California, USA.
Abstract
BACKGROUND: Urine biomarkers of kidney tubule health may distinguish aspects of kidney damage that cannot be captured by current glomerular measures. Associations of clinical risk factors with specific kidney tubule biomarkers have not been evaluated in detail.
METHODS: We performed a cross-sectional study in the Systolic Blood Pressure Intervention Trial among 2,436 participants with a baseline…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans